CClinicalTrials.gg
Status unknownNCT05436483Updated Jun 29, 2022

Preliminary Establishment of the Medical Reference Range of Serum Vitamin K2 in Chinese Healthy Adults

An observational study in Health, Subjective, sponsored by Peking University Third Hospital. Status unknown. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-29.

Sponsored by Peking University Third Hospital · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
465
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Osteocalcin is a type of vitamin K2-dependent protein, and many studies have confirmed that vitamin K2 has anti-osteoporosis effects, and has preventive and therapeutic effects on a variety of diseases such as nervous system, cardiovascular disease, immune disease, and glucose metabolism. However, as a pleiotropic vitamin and nutrient, vitamin K2 does not have an exact normal range like other vitamins, when it needs to be supplemented, and in what regimen. Different organizations have different opinions on the recommended intake of vitamin K. Thus, this study intends to preliminarily obtain the reference interval of serum vitamin K2 by conducting clinical research in healthy people in the Beijing-Tianjin-Hebei region, and analyzes different factors, such as gender, age, and place of residence, to compare their level differences and changing trends, and to provide data reference for the recommended intake of vitamin K2 for people with vitamin K2 deficiency.

02

Conditions studied

  • Health, Subjective
03

In context

Lead sponsor

Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy subjects

Inclusion criteria

  • People aged over 18.
  • People with normal routine blood test.
  • Willing to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with congenital metabolic problems and endocrine diseases.
  • Treatment with any investigational drug within the past 3 months.
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
465 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Concentration of vitamin K2

    Vitamin K2 concentration in serum

    Time frame: During the procedure of regular physical checkups

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05436483
Lead sponsor
Peking University Third Hospital
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Jul 31, 2022 (estimated)
Primary completion
Jul 30, 2023 (estimated)
Completion
Aug 31, 2023 (estimated)
Last update
Jun 29, 2022

Study contacts

Qi Liu, Ph. D.
Contact
liuqicpu@hotmail.com
+8615501060136
Chunli Song, M.D.; Ph. D.
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion